Tyrosine Kinase Inhibitor Dosing Patterns in Elderly Patients with Chronic Myeloid Leukemia

We investigated tyrosine kinase inhibitor (TKI) dosing patterns and survival in elderly chronic myeloid leukemia (CML) patients: Approximately 66% of 378 patients were on reduced TKIs dose at last visit; except imatinib, dose densities were

Source: Clinical Lymphoma, Myeloma and Leukemia - August 28, 2019 Category: Hematology Authors: Hee Yeon Seo, Tae Hwa Ko, Shin Young Hyun, Hyebin Song, Seung Taek Lim, Kwang Yong Shim, Jong In Lee, Jee Hyun Kong Tags: Original Study Source Type: research